Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. LDOS
LDOS logo

LDOS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Leidos Holdings Inc (LDOS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
101.440
1 Day change
-5.30%
52 Week Range
205.770
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Leidos Holdings Inc (LDOS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently under pressure due to significant downgrades from analysts, concerns over its healthcare business, and bearish technical indicators. While hedge funds are buying, the lack of positive trading signals and the absence of strong catalysts suggest holding off on investment for now.

Technical Analysis

The technical indicators for LDOS are bearish. The MACD is negatively expanding (-1.041), RSI is at 6.713 indicating oversold conditions, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 109.047 and S2 at 104.063.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
10
Buy
6

Positive Catalysts

  • Hedge funds are increasing their positions, with buying activity up 348.79% over the last quarter.

Neutral/Negative Catalysts

  • Significant analyst downgrades from BofA and Jefferies, citing pressures in the healthcare business and limited EPS growth potential. The stock recently dropped 11% following these downgrades. Additionally, technical indicators are bearish, and there is no recent congress trading data or strong trading signals.

Financial Performance

No financial performance data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have downgraded the stock significantly. BofA downgraded LDOS to Neutral from Buy, reducing the price target to $125 from $200. Jefferies also downgraded the stock to Hold from Buy, with a price target of $140, down from $185. Other firms have also lowered price targets, citing pressures in the healthcare and defense portfolios.

Wall Street analysts forecast LDOS stock price to rise
11 Analyst Rating
Wall Street analysts forecast LDOS stock price to rise
7 Buy
4 Hold
0 Sell
Moderate Buy
Current: 107.120
sliders
Low
178
Averages
219.7
High
235
Current: 107.120
sliders
Low
178
Averages
219.7
High
235
BofA
Buy
to
Neutral
downgrade
$200 -> $125
AI Analysis
2026-06-17
New
Reason
BofA
Price Target
$200 -> $125
AI Analysis
2026-06-17
New
downgrade
Buy
to
Neutral
Reason
As previously reported, BofA downgraded Leidos to Neutral from Buy with a price target of $125, down from $200, citing increasing pressure across the "once blooming" healthcare portfolio. The managed healthcare business has been a standout performer for some time, but the firm sees downward pressure in the near term as the Defense Health Agency works on trying to work directly with suppliers in the Defense Healthcare Management System Modernization maintenance phase and the Medical Disability Exams upcoming recompete weighs on Leidos' future share and pricing power, the analyst tells investors.
BofA
Buy
to
Neutral
downgrade
$200 -> $125
2026-06-17
New
Reason
BofA
Price Target
$200 -> $125
2026-06-17
New
downgrade
Buy
to
Neutral
Reason
BofA downgraded Leidos to Neutral from Buy with a price target of $125, down from $200.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for LDOS
Unlock Now

People Also Watch